Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new ...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative ...
The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive ...
The findings, from an international clinical trial, reinforce earlier findings of the benefits of the drug -- trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate -- in these patients ...
News Medical on MSN7d
New drug shows strong activity against brain metastases in HER2-positive breast cancerA drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback